SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AB InBev Q3 Earnings Beat Estimates on Revenue Growth & Premiumization

BUD's Q3 earnings and revenues beat estimates, fueled by premiumization, strong megabrands and digital growth, despite regional weakness and margin pressures.

FEMSA Q3 Earnings Miss Estimates Despite Strong OXXO Sales

FMX's Q3'26 earnings miss estimates despite strong OXXO Mexico sales and revenue growth, as margin pressures across key divisions weigh on profitability.

Fed Holds Interest Rates Steady Amid Inflationary Concerns: 4 Safe Bets 

With inflation stubbornly high and rate hikes still possible, ADM, DEO, LW and SJM offer defensive consumer staples exposure, low betas and attractive dividend yields.

All You Need to Know About Diageo (DEO) Rating Upgrade to Strong Buy

Diageo (DEO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Buy Stocks for October 28th

AFRM, WDC, OVV, E and DEO have been added to the Zacks Rank #1 (Strong Buy) List on October 28th, 2026.

Best Value Stocks to Buy for October 28th

DEO, E and OVV made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 28th, 2026.

Best Income Stocks to Buy for October 28th

E, OVV and DEO made it to the Zacks Rank #1 (Strong Buy) income stocks list on October 28th, 2026.

AB InBev's U.S. Beyond Beer Sales Surge in Q2: Can the Momentum Last?

BUD's U.S. Beyond Beer revenues surge in Q2 2026, fueled by Cutwater's triple-digit growth, RTD innovation and expanding distribution.

The Zacks Analyst Blog Highlights Archer-Daniels-Midland, Dole, Diageo and The Hershey

Archer-Daniels-Midland, Dole, Diageo and Hershey offer defensive consumer staples exposure as sentiment declines, inflation rises and market volatility persists.

Top Stock Picks for Week of October 12, 2026

The World's Largest Social Media Platform and a Global Alcoholic Beverages Company are Highlighted.

Diageo Plc engages in the production and distribution of alcoholic beverages. The firm brands include Johnnie Walker, Crown Royal, J&B and Buchanan’s whiskies, Smirnoff, Ciroc and Ketel One vodkas, Captain Morgan, Baileys, Don Julio, Casamigos, Tanqueray, and Guinness. It operates through the following geographical segments: North America, Europe, Asia Pacific, Latin America and Caribbean, Africa, and Corporate and Other. The company was founded on October 21, 1886 and is headquartered in London, the United Kingdom.

Diageo plc - ADR

Why Is Diageo Stock Rising Premarket Today?

Equity

Bearish Sentiment

<ul><li>Diageo is trimming costs and selling global holdings amid a pullback in alcohol demand that is pressuring the business.</li><li>According to Bloomberg, the British group is working with advisors to sell its 63% stake in Sichuan Swellfun Co., a Shanghai-listed company.</li><li>DEO stock is up by over 5% so far this year, after years in decline.</li></ul>British liquor giant Diageo Plc is exploring options for its China assets, including a potential sale, as part of broader portfolio rebalancing amid tariff pressures and shifting drinking habits, Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-01-13/diageo-is-said-to-weigh-options-for-china-assets-including-sale">reported</a>.Diageo, known for Johnnie Walker whiskey and Smirnoff vodka, is working with Goldman Sachs and UBS Group to review its operations, which include a more than 63% stake in Shanghai-listed Sichuan Swellfun Co., the report said, citing anonymous sources.&nbsp;<a href="https://stocktwits.com/symbol/DEO">U.S.-listed shares of Diageo</a> rose nearly 1% in early premarket trading on Tuesday, following the report.&nbsp;<h2 class="st-heading-2">Firms Review China Exposure</h2>If the talks materialize in a divestiture, Diageo would be the latest global company to partially or fully exit China.Last year, Starbucks sold a majority stake in its China business to private equity firm Boyu Capital for $4 billion, while Restaurant Brands International made a similar move with the local unit of its Burger King chain.&nbsp;<h2 class="st-heading-2">Declining Alcohol Consumption&nbsp;</h2>The company cut its sales and profit outlook in November amid declining consumer alcohol consumption, particularly in key markets such as the U.S. and China.&nbsp;Diageo has responded by cutting costs and selling its global holdings. In December, it agreed to sell a majority stake in East African Breweries to Japan’s Asahi Group Holdings Ltd. for $2.3 billion. Meanwhile, the company appointed former Tesco boss Dave Lewis as its CEO in November, after a months-long search.Diageo stock declined 32% over 2025, its fourth straight year of decline. Shares are up 5.4% so far this month.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A limited edition bottle of Johnnie Walker whisky called "Jane Walker" is displayed on March 3, 2018 in Sacramento, California.(Photo by Justin Sullivan/Getty Images)

The liquor giant is reportedly exploring options for its Chinese assets.

Diageo plc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$DEO This one's looking real good since last week's Monday low and "lonely island" setup. 
 
Took an entry on a break and retest of the $86.50 zone on Friday. 
Took some profits today on buy-side liquidity test but very hungry for more to take to the $95 target. 
 
Maybe we see a tap of $86 again before the larger move?

The Trader B

$DEO Broke intermediate downtrend but still in long term downtrend dating back to 22 bear market. A crazy amt of divergence on indicators from my view. Watching to take position likely sooner rather than later. Wait and see on longer term downtrend decision

Friend of Bill

$DEO As an investor / trader of this stock and an Extra Stout drinker the abandonment of the brewery here was possibly necessary but has led to shortage of the brew and escalating pricing.  They need to cut a deal w/ Trump on tariffs on the Irish original beer and get more flowing here.

Feed

News

Sentiment

Earnings

Fundamentals

Info

DEO Diageo plc

Fundamentals

Latest DEO News